{"id":70567,"date":"2026-04-13T18:19:29","date_gmt":"2026-04-13T12:49:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70567"},"modified":"2026-04-13T18:19:30","modified_gmt":"2026-04-13T12:49:30","slug":"bal-pharma-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/","title":{"rendered":"Bal Pharma Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Bal Pharma (BALPHARMA) Q4 FY26 results are scheduled for May 15, 2026, when the company&#8217;s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 148 as of April 2026 \u2014 down -32% from its 52-week high of Rs 228 \u2014 the stock has been under pressure alongside its peers in the Pharmaceuticals \/ Generics sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.<\/p><p>Bal Pharma&#8217;s Q4 FY26 earnings will be watched for signals on the company&#8217;s +10% revenue YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get free investment predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Bal_Pharma_Q4_Results_2026_Date\" title=\"Bal Pharma Q4 Results 2026 Date\">Bal Pharma Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Why_Q4_FY26_Matters\" title=\"Why Q4 FY26 Matters\">Why Q4 FY26 Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Bal_Pharma_Q4_FY26_Earnings_Estimates\" title=\"Bal Pharma Q4 FY26 Earnings Estimates\">Bal Pharma Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#5_Key_Factors_Driving_Bal_Pharma_Q4_FY26_Performance\" title=\"5 Key Factors Driving Bal Pharma Q4 FY26 Performance\">5 Key Factors Driving Bal Pharma Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#1_Branded_Generic_Domestic_Growth\" title=\"1. Branded Generic Domestic Growth\">1. Branded Generic Domestic Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#2_API_Manufacturing\" title=\"2. API Manufacturing\">2. API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#3_Export_Market_Development\" title=\"3. Export Market Development\">3. Export Market Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#4_Field_Force_Productivity\" title=\"4. Field Force Productivity\">4. Field Force Productivity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#5_DRHP_Filing\" title=\"5. DRHP Filing\">5. DRHP Filing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#5_Risks_to_Watch_in_Bal_Pharma_Q4_FY26\" title=\"5 Risks to Watch in Bal Pharma Q4 FY26\">5 Risks to Watch in Bal Pharma Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Risk_1_IPM_Slowdown\" title=\"Risk 1: IPM Slowdown\">Risk 1: IPM Slowdown<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Risk_2_FDA_Regulatory_Risk\" title=\"Risk 2: FDA Regulatory Risk\">Risk 2: FDA Regulatory Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Risk_3_Competition_from_Generic_Chains\" title=\"Risk 3: Competition from Generic Chains\">Risk 3: Competition from Generic Chains<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Risk_4_Working_Capital\" title=\"Risk 4: Working Capital\">Risk 4: Working Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Risk_5_Thin_Margins\" title=\"Risk 5: Thin Margins\">Risk 5: Thin Margins<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Bal_Pharma_Share_Price_and_Analyst_Ratings\" title=\"Bal Pharma Share Price and Analyst Ratings\">Bal Pharma Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_When_is_Bal_Pharma_Q4_results_2026_date\" title=\"Q: When is Bal Pharma Q4 results 2026 date?\">Q: When is Bal Pharma Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_What_is_Bal_Pharma_Q4_FY26_revenue_estimate\" title=\"Q: What is Bal Pharma Q4 FY26 revenue estimate?\">Q: What is Bal Pharma Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_What_is_Bal_Pharma_Q4_FY26_PAT_estimate\" title=\"Q: What is Bal Pharma Q4 FY26 PAT estimate?\">Q: What is Bal Pharma Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_Will_Bal_Pharma_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Bal Pharma declare a dividend in Q4 FY26?\">Q: Will Bal Pharma declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_What_is_Bal_Pharma_current_share_price\" title=\"Q: What is Bal Pharma current share price?\">Q: What is Bal Pharma current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_What_were_Bal_Pharma_Q3_FY26_results\" title=\"Q: What were Bal Pharma Q3 FY26 results?\">Q: What were Bal Pharma Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"Q: When do TCS and Infosys announce Q4 results 2026?\">Q: When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Q_Is_Bal_Pharma_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is Bal Pharma a good investment ahead of Q4 results?\">Q: Is Bal Pharma a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bal_Pharma_Q4_Results_2026_Date\"><\/span><strong>Bal Pharma Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Bal Pharma Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.<\/p><p>Here is a broader view of the Q4 FY26 results calendar for reference:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Key Metric<\/strong><\/td><\/tr><tr><td>[object Object]<\/td><td>April 9, 2026 (Declared)<\/td><td>FY27 revenue guidance, deal TCV<\/td><\/tr><tr><td>[object Object]<\/td><td>April 23, 2026<\/td><td>CC growth guidance for FY27<\/td><\/tr><tr><td>Bharat Electronics (BEL)<\/td><td>May 8, 2026<\/td><td>Order book execution, EBITDA margin<\/td><\/tr><tr><td>Bharat Forge<\/td><td>May 10, 2026<\/td><td>Global CV + defence execution<\/td><\/tr><tr><td>Bal Pharma<\/td><td>May 15, 2026<\/td><td>See estimates below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Q4_FY26_Matters\"><\/span><strong>Why Q4 FY26 Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.<\/p><p>For Bal Pharma specifically, Q4 FY26 captures the peak season dynamics of the Pharmaceuticals \/ Generics sector. Management&#8217;s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bal_Pharma_Q4_FY26_Earnings_Estimates\"><\/span><strong>Bal Pharma Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181636\/Bal-Pharma-Q4-FY26-analyst-consensus-estimates-%E2%80%94-Revenue-PAT-Margin-1024x536.jpg\" alt=\"Bal Pharma Q4 FY26 analyst consensus estimates \u2014 Revenue, PAT, Margin\" class=\"wp-image-70571\"\/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium research on Univest<\/strong><\/a>.<\/p><p>Based on publicly available analyst consensus, here are the Q4 FY26 estimates for Bal Pharma:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Trend<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 285 Cr<\/td><td>Rs 258 Cr<\/td><td>QoQ expected improvement<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs 12 Cr<\/td><td>Rs 10 Cr<\/td><td>Normalisation expected<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 10%<\/td><td>Q3 FY26 margin<\/td><td>QoQ trend<\/td><\/tr><tr><td>Volume \/ Growth Driver<\/td><td>+10% revenue YoY<\/td><td>Prior quarter<\/td><td>YoY<\/td><\/tr><tr><td>Dividend (Expected)<\/td><td>Rs 0.50 (expected)<\/td><td>FY26 interim dividends<\/td><td>Final dividend<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <strong>Bal Pharma<\/strong> live fundamentals on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time Q4 result alerts and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_Driving_Bal_Pharma_Q4_FY26_Performance\"><\/span><strong>5 Key Factors Driving Bal Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Branded_Generic_Domestic_Growth\"><\/span><strong>1. Branded Generic Domestic Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bal Pharma&#8217;s India branded generic business across cardiovascular, anti-infective, and pain management therapeutic areas is growing at 8-10% annually in line with the IPM.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_API_Manufacturing\"><\/span><strong>2. API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The company manufactures APIs for internal use and third-party customers. API segment margins are higher than finished dosage forms, and any new API customer wins would be positive.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Export_Market_Development\"><\/span><strong>3. Export Market Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bal Pharma has been developing export markets in Africa, Southeast Asia, and the Middle East for its generic formulations. Export revenue growth is incremental to domestic growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Field_Force_Productivity\"><\/span><strong>4. Field Force Productivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Improving prescription productivity per medical representative is the primary lever for domestic revenue growth. Q4 management commentary on MR efficiency would be a quality indicator.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_DRHP_Filing\"><\/span><strong>5. DRHP Filing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Any DRHP filing or corporate action announcement alongside Q4 results would be a market catalyst.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Bal_Pharma_Q4_FY26\"><\/span><strong>5 Risks to Watch in Bal Pharma Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_IPM_Slowdown\"><\/span><strong>Risk 1: IPM Slowdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Indian Pharmaceutical Market growing below 8% would impact Bal Pharma&#8217;s branded generic revenue.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_FDA_Regulatory_Risk\"><\/span><strong>Risk 2: FDA Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Any FDA inspection observation on export facilities would create compliance costs and potential revenue disruption.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_Competition_from_Generic_Chains\"><\/span><strong>Risk 3: Competition from Generic Chains<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Pharmacy chain private labels compete in the generic medicine segment, putting pressure on branded generic pricing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_4_Working_Capital\"><\/span><strong>Risk 4: Working Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Pharmaceutical distribution has long receivable cycles from distributors and government institutions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_5_Thin_Margins\"><\/span><strong>Risk 5: Thin Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>At 10% EBITDA, margin recovery to 12%+ requires revenue scale without proportionate cost increases.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bal_Pharma_Share_Price_and_Analyst_Ratings\"><\/span><strong>Bal Pharma Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663.jpeg\" alt=\"Bal Pharma share price and analyst ratings \u2014 Q4 FY26 preview\" class=\"wp-image-70568\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 148<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 228<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 128<\/td><\/tr><tr><td>1-Year Return<\/td><td>-32%<\/td><\/tr><tr><td>Market Capitalisation<\/td><td>Rs 380 Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharmaceuticals \/ Generics<\/td><\/tr><tr><td>NSE Ticker<\/td><td>BALPHARMA<\/td><\/tr><\/tbody><\/table><\/figure><p>Analyst ratings and target prices based on publicly available brokerage research:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>Geojit Financial<\/td><td>ADD<\/td><td>Rs 180<\/td><td>Branded generic growth on track<\/td><\/tr><tr><td>HDFC Securities<\/td><td>NEUTRAL<\/td><td>Rs 155<\/td><td>Scale needed for meaningful rerating<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Bal Pharma Q4 FY26 will reflect India pharma market trends. Revenue above Rs 285 crore with PAT above Rs 12 crore would be a beat. The API and export segments are the incremental growth catalysts beyond domestic branded generics.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_is_Bal_Pharma_Q4_results_2026_date\"><\/span><strong>Q: When is Bal Pharma Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bal Pharma Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bal_Pharma_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is Bal Pharma Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Bal Pharma Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 258 Cr. Actual Q4 results may vary based on operating conditions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bal_Pharma_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is Bal Pharma Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Bal Pharma Q4 FY26 net profit (PAT) is Rs 12 Cr. Q3 FY26 actual PAT was Rs 10 Cr. Estimates are indicative and not guaranteed.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_Bal_Pharma_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Bal Pharma declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bal Pharma is expected to declare Rs 0.50 (expected) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bal_Pharma_current_share_price\"><\/span><strong>Q: What is Bal Pharma current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bal Pharma is trading at Rs 148 as of April 2026, with a 52-week range of Rs 128 to Rs 228. The 1-year return is -32%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_Bal_Pharma_Q3_FY26_results\"><\/span><strong>Q: What were Bal Pharma Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Bal Pharma reported revenue of Rs 258 Cr and net profit (PAT) of Rs 10 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>Q: When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026 (see the Bal Pharma earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Bal_Pharma_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is Bal Pharma a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Bal Pharma trades at Rs 148 with a 52-week range of Rs 128 to Rs 228. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/techno-electric-and-engineering-q4-results-2026\">Techno Electric &amp; Engineering Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/jbm-auto-q4-results-2026\">JBM Auto Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/varroc-engineering-q4-results-2026\">Varroc Engineering Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/hitachi-energy-india-q4-results-2026\">Hitachi Energy India Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cg-power-and-industrial-solutions-q4-results-2026\">CG Power and Industrial Solutions Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Bal Pharma (BALPHARMA) Q4 FY26 results are scheduled for May 15, 2026, when the company&#8217;s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 148 as of April 2026 \u2014 down -32% from its 52-week high of Rs 228 \u2014 the stock has been under pressure alongside its<\/p>\n","protected":false},"author":28,"featured_media":70574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-70567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776084594:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-663.jpeg\";a:2:{s:2:\"id\";i:70568;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181519\/image-663.jpeg\";a:2:{s:2:\"id\";i:70568;s:11:\"source_type\";s:13:\"media-library\";}s:121:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Bal-Pharma-Q4-FY26-analyst-consensus-estimates-\u2014-Revenue-PAT-Margin.jpg\";a:2:{s:2:\"id\";i:70571;s:11:\"source_type\";s:13:\"media-library\";}s:130:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Bal-Pharma-Q4-FY26-analyst-consensus-estimates-\u2014-Revenue-PAT-Margin-1024x536.jpg\";a:2:{s:2:\"id\";i:70571;s:11:\"source_type\";s:13:\"media-library\";}s:153:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181636\/Bal-Pharma-Q4-FY26-analyst-consensus-estimates-\u2014-Revenue-PAT-Margin.jpg\";a:2:{s:2:\"id\";i:70571;s:11:\"source_type\";s:13:\"media-library\";}s:162:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181636\/Bal-Pharma-Q4-FY26-analyst-consensus-estimates-\u2014-Revenue-PAT-Margin-1024x536.jpg\";a:2:{s:2:\"id\";i:70571;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_description":["Bal Pharma Q4 results date is May 15, 2026. Revenue estimate Rs 285 Cr, PAT estimate Rs 12 Cr. Key factors, risks, analyst ratings and Bal Pharma share price outlook."],"rank_math_title":["Bal Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Bal Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["70574"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7992"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13181832\/Bal-Pharma-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70567"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70567\/revisions"}],"predecessor-version":[{"id":70578,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70567\/revisions\/70578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70574"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}